Core Insights - The article highlights the challenges faced by grassroots medical institutions in China due to a strong cold wave and a surge in respiratory infectious diseases, particularly influenza [1][2] - The digital pharmaceutical platform, Yaoshi Bang, is actively addressing the medication supply and treatment service demands in grassroots healthcare through its digital supply chain system [1] Group 1: Company Performance - Yaoshi Bang has established deep strategic partnerships with several domestic pharmaceutical companies to ensure stable supply of core medications, including a full range of influenza treatment drugs like Oseltamivir [1] - The platform reported a significant increase in sales of influenza-related medications, with an overall sales growth of 36% year-on-year since October 2025, and a 120% increase in sales of Oseltamivir products [1] - The company's own brand, "Leyaoshi," saw a sales growth exceeding 135% year-on-year due to its cost-effective offerings [1] Group 2: Service Innovations - Yaoshi Bang has introduced the "Spectrum Cabin" smart healthcare solution to empower the diagnostic end, alleviating pressure on grassroots healthcare during the flu season [2] - The core product, the Immunity Small Box, supports rapid testing for influenza A and B, with a month-on-month increase in testing numbers exceeding 60% in October [2] - The integration of upstream pharmaceutical resources, intelligent scheduling, and downstream smart testing services enhances Yaoshi Bang's ability to provide comprehensive support for medication supply and treatment during the flu season [2]